RxDoctor Payments Data

Comfort Impraim

Family · Tucson, AZNPI 1144610239

Payments from drug & device makers

$2,699in general payments, 2019–2025

Across 130 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$646
  • AbbVie$478
  • Teva Pharmaceuticals USA, Inc.$449
  • Otsuka America Pharmaceutical, Inc.$324
  • Johnson & Johnson$275
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$115
  • plus $411 from 7 others

What the payments were for

  • Food & beverage$2,67199%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,699 in reported general payments places this provider in the 85th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$18,180
Medicare patients
50
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide55$59,365
EliquisApixaban53$34,837
JardianceEmpagliflozin39$23,357
Spiriva HandihalerTiotropium Bromide42$23,340
XareltoRivaroxaban34$19,723
RybelsusSemaglutide13$12,843
MyrbetriqMirabegron25$11,917
Advair HfaFluticasone Propion/Salmeterol21$8,458
VascepaIcosapent Ethyl44$8,024
Incruse ElliptaUmeclidinium Bromide19$7,145
JanuviaSitagliptin Phosphate14$6,446
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,352
Albuterol Sulfate HfaAlbuterol Sulfate119$4,232
Atorvastatin Calcium368$3,394
Gabapentin160$2,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$30$59,36555 claims
Johnson & JohnsonXarelto$275$19,72334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,119 family providers in Arizona.

Other family in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →